High-flow nasal cannula therapy with sequential noninvasive ventilation versus noninvasive ventilation alone as the initial ventilatory strategy in acute COPD exacerbations: study protocol for a randomized controlled trial

• DOI: 10.1186/s13063-022-06963-w
• Publication Date: 2022-12-29T05:03:03Z
• Authors: Shuai Liu; Joseph Harold Wal...; Huadong Zhu; Yan Li; Chunting Wang; Jihai Liu
• Keywords: Nasal cannula; Noninvasive Ventilation

Abstract Background Noninvasive ventilation (NIV) is the recommended mode of used in acute respiratory failure secondary to an exacerbation chronic obstructive pulmonary disease (AECOPD). Recent data has shown that high-flow nasal cannula (HFNC) treatment can be alternative for patients with hypercapnic failure. The purpose this study evaluate HFNC sequential NIV versus alone as initial ventilatory strategy AECOPD. Methods This investigator-initiated, unblinded, single center, randomized controlled trial will conducted emergency department, intensive care unit, or unit a tertiary-care urban teaching hospital. A total 66 enrolled and into intervention group (HFNC NIV) control (NIV group). primary endpoint mean difference PaCO 2 from baseline 24 h after randomization. Secondary endpoints include 6, 12, 18 h, well dyspnea score, overall discomfort rate failure, rate, endotracheal intubation, length hospital stay, mortality. Discussion Taking advantages both on AECOPD account, we designed clinical investigate combination these strategies. help us understand how compares treating patients. Trial registration ChiCTR2100054809.